

09921880

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653sxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 27 Oct 21 EVENTLINE has been reloaded  
NEWS 28 Oct 24 BEILSTEIN adds new search fields  
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 32 Nov 25 More calculated properties added to REGISTRY  
NEWS 33 Dec 02 TIBKAT will be removed from STN  
NEWS 34 Dec 04 CSA files on STN  
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 36 Dec 17 TOXCENTER enhanced with additional content  
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 38 Dec 30 ISMEC no longer available  
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003  
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003  
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,

08/03/01

09921880

ENERGY, INSPEC

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,  
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:06:25 ON 30 JAN 2003

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:06:52 ON 30 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

DICTIONARY FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

=> s c.....c/sqsp

L1 168545 C.....C/SQSP

=> l1 and sql<=210

08/03/01

09921880

L1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 and sql<=210

4885277 SQL<=210

L2 60610 L1 AND SQL<=210

=> FIL BIOSIS MEDLINE CAPLUS EMBASE SCISEARCH PCTFULL USPATFULL USPAT2 EUROPATFULL  
COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

45.92

46.13

FILE 'BIOSIS' ENTERED AT 11:29:46 ON 30 JAN 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 11:29:46 ON 30 JAN 2003

FILE 'CAPLUS' ENTERED AT 11:29:46 ON 30 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:29:46 ON 30 JAN 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 11:29:46 ON 30 JAN 2003

COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'PCTFULL' ENTERED AT 11:29:46 ON 30 JAN 2003

COPYRIGHT (C) 2003 Univentio

FILE 'USPATFULL' ENTERED AT 11:29:46 ON 30 JAN 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:29:46 ON 30 JAN 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 11:29:46 ON 30 JAN 2003

COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

=> s l2 and (factor or thrombosis or vascular or thrombotic)

TOO MANY TERMS FOR FILE CROSSOVER IN L2

There are limits on the size of an answer set being crossed over from

one file to another. Enter HELP CROSSOVER at an arrow prompt (=>)

for specific information.

=> s l2 and (factor)

TOO MANY TERMS FOR FILE CROSSOVER IN L2

There are limits on the size of an answer set being crossed over from

one file to another. Enter HELP CROSSOVER at an arrow prompt (=>)

for specific information.

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

9.22

55.35

FILE 'REGISTRY' ENTERED AT 11:32:16 ON 30 JAN 2003

08/03/01

09921880

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5  
DICTIONARY FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s cwtwetc/sqsp  
L3 14 CWTWETC/SQSP

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	26.90	82.25

FILE 'BIOSIS' ENTERED AT 11:33:06 ON 30 JAN 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 11:33:06 ON 30 JAN 2003

FILE 'CAPLUS' ENTERED AT 11:33:06 ON 30 JAN 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:33:06 ON 30 JAN 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 11:33:06 ON 30 JAN 2003  
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'PCTFULL' ENTERED AT 11:33:06 ON 30 JAN 2003  
COPYRIGHT (C) 2003 Univentio

FILE 'USPATFULL' ENTERED AT 11:33:06 ON 30 JAN 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:33:06 ON 30 JAN 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 11:33:06 ON 30 JAN 2003  
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

=> s 13  
'SQSP' IS NOT A VALID FIELD CODE

08/03/01

09921880

'SQSP' IS NOT A VALID FIELD CODE  
'SQSP' IS NOT A VALID FIELD CODE  
L4 3 L3

=> d l4 py pn au ti so ab

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS  
PY 2001  
AU Roberge, Martin; Santell, Lydia; Dennis, Mark S.; Eigenbrot, Charles;  
Dwyer, Mary A.; Lazarus, Robert A.  
TI A novel exosite on coagulation factor VIIa and its molecular interactions  
with a new class of peptide inhibitors  
SO Biochemistry (2001), 40(32), 9522-9531  
CODEN: BICHAW; ISSN: 0006-2960  
AB A new inhibitory peptide binding exosite on the protease domain of  
coagulation Factor VIIa (FVIIa) has been identified. A novel series of  
peptide inhibitors of FVIIa, termed the "A-series" peptides, identified  
from peptide phage libraries and exemplified by peptide A-183,  
specifically bind at a site that is distinct from both the active site and  
the exosite of another recently described peptide inhibitor of FVIIa,  
E-76. Peptide A-183 prolonged TF-dependent clotting in human, but not  
rabbit plasma. Thus, a panel of human FVIIa mutants, contg. 70 of the 76  
rabbit sequence differences in the protease domain, localized the binding  
site to residues in the 60s loop and the C-terminus. The location of the  
exosite was refined by a series of FVIIa alanine mutants, which showed  
that proximal residues Trp 61 and Leu 251 were crit. for binding. Kinetic  
and equil. binding consts. for zymogen FVII, FVIIa and TF.cntdot.FVIIa  
were detd. using immobilized N-terminal biotinylated A-183 by surface  
plasmon resonance. No peptide binding to nine other human serine  
proteases was obsd. Key residues on the peptide were detd. from binding  
to FVIIa and inhibition of FX activation using a series of alanine mutants  
of A-183 fused to the Z domain of protein A. Anal. of the mutagenesis  
data is presented in the context of a crystal structure of A-183 in  
complex with a version of zymogen FVII. The shape and proximity of this  
exosite to the active site may lend itself towards the design of new  
anticoagulants that inhibit FVIIa.

=> d l4 py pn au ti so ab 2-3

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS  
PY 2001  
AU Dennis, Mark S.; Roberge, Martin; Quan, Cliff; Lazarus, Robert A.  
TI Selection and characterization of a new class of peptide exosite  
inhibitors of coagulation factor VIIa  
SO Biochemistry (2001), 40(32), 9513-9521  
CODEN: BICHAW; ISSN: 0006-2960  
AB A new series of peptide inhibitors of human Factor VIIa (FVIIa) has been  
identified and affinity matured from naive and partially randomized  
peptide phage libraries selected against the immobilized tissue  
factor.cntdot.Factor VIIa (TF.cntdot.FVIIa) complex. These "A-series"  
peptides contain a single disulfide bond and a 13-residue minimal core  
required for maximal affinity. They are exemplified by peptide A-183  
(EEWEVLCWTWETCER), which binds at a newly identified exosite on the FVIIa  
protease domain, described in the accompanying report [Roberge, M.,  
Santell, L., Dennis, M. S., Eigenbrot, C., Dwyer, M. A., and Lazarus, R.  
A. (2001) Biochem. 40, XXXXX-XXXXX]. A-183 was obtained from a trypsin  
digest of A-100-Z, a recombinant protein comprising A-183 and the Z domain  
of protein A. Surprisingly, A-183 was a very potent inhibitor of  
TF.cntdot.FVIIa, inhibiting activation of Factor X (FX) and Factor IX and

09921880

amidolytic activity of Chromozym t-PA with IC50 values of 1.6  $\pm$  1.2, 3.5  $\pm$  0.3, and 8.5  $\pm$  3.5 nM, resp. Kinetic anal. revealed that A-183 was a partial (hyperbolic) mixed-type inhibitor of FX activation having a Ki of 200 pM as well as a partial competitive inhibitor of amidolytic activity. The A-series peptides were also specific and potent inhibitors of TF-dependent clotting as measured in a prothrombin time (PT) clotting assay and had no effect on the TF-independent activated partial thromboplastin time. At satg. concns. of peptide, the maximal extent by which A-183 and A-100-Z inhibited the rate of FX activation was 78  $\pm$  3 and 89  $\pm$  6%, resp. The degree of inhibition of the rate of FX activation correlated with a max. fold prolongation in the PT assay of 1.8-fold for A-183 and 3.3-fold for A-100-Z. The A-series peptides represent a new class of peptide exosite inhibitors that are capable of attenuating, rather than completely inhibiting, the activity of TF.cntdot.FVIIa, potentially leading to anticoagulants with an increased therapeutic window.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS

PY 2001

2002

PATENT NO. KIND DATE

-----

PI WO 2001010892 A2 20010215  
EP 1203014 A2 20020508

IN Dennis, Mark S.

TI Factor VIIa antagonists for diagnostic or therapeutic use

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

AB This invention provides novel compds. which prevent or block a FVIIa mediated or assocd. process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compds. of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the assocn. of FVII or FVIIa with a peptide compd. of the present invention. The invention also provides pharmaceutical compns. comprising the novel compds. as well as their use in diagnostic, therapeutic, and prophylactic methods.

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:n

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

17.86

100.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.95

-1.95

FILE 'REGISTRY' ENTERED AT 11:35:06 ON 30 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

08/03/01

09921880

DICTIONARY FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s l1 and sql<=20  
1496100 SQL<=20  
L5 4615 L1 AND SQL<=20

=> s l1 and sql<=10  
398043 SQL<=10  
L6 1711 L1 AND SQL<=10

	SINCE FILE	TOTAL
	ENTRY	SESSION
=> FIL BIOSIS MEDLINE CAPLUS EMBASE SCISEARCH PCTFULL USPATFULL USPAT2 EUROPATFULL		
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	9.24	109.35

	SINCE FILE	TOTAL
	ENTRY	SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	0.00	-1.95

FILE 'BIOSIS' ENTERED AT 11:36:13 ON 30 JAN 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 11:36:13 ON 30 JAN 2003

FILE 'CAPLUS' ENTERED AT 11:36:13 ON 30 JAN 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:36:13 ON 30 JAN 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 11:36:13 ON 30 JAN 2003  
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'PCTFULL' ENTERED AT 11:36:13 ON 30 JAN 2003  
COPYRIGHT (C) 2003 Univentio

FILE 'USPATFULL' ENTERED AT 11:36:13 ON 30 JAN 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:36:13 ON 30 JAN 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 11:36:13 ON 30 JAN 2003  
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

=> s l5

08/03/01

09921880

'20' NOT A VALID FIELD CODE  
'SQSP' IS NOT A VALID FIELD CODE  
5 FILES SEARCHED...  
'20' NOT A VALID FIELD CODE  
'SQSP' IS NOT A VALID FIELD CODE  
'20' NOT A VALID FIELD CODE  
'SQSP' IS NOT A VALID FIELD CODE  
L7 2997 L5

=> s 17 and (factor or thrombosis)  
L8 752 L7 AND (FACTOR OR THROMBOSIS)

=> s 17 and (factor (w) VII)  
L9 18 L7 AND (FACTOR (W) VII)

=> dup rem 19  
PROCESSING COMPLETED FOR L9  
L10 18 DUP REM L9 (0 DUPLICATES REMOVED)

=> s 17 and ((factor (w) VII) or FVII or FX or X)  
7 FILES SEARCHED...  
L11 530 L7 AND ((FACTOR (W) VII) OR FVII OR FX OR X)

=> s 17 and ((factor (w) VII) or FVII or FX)  
L12 19 L7 AND ((FACTOR (W) VII) OR FVII OR FX)

=> s 112 and py<=2000  
1 FILES SEARCHED...  
4 FILES SEARCHED...  
L13 13 L12 AND PY<=2000

=> d 113 1-13 py pn au ti so ab

L13 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2003 ACS  
PY 1997

AU Orning, Lars; Stephens, Ross W.; Petersen, Lizette B.; Hamers, Maria  
J.A.G.; Stormorken, Helge; Sakariassen, Kjell S.

TI A peptide sequence from the EGF-2 like domain of **FVII** inhibits  
TF-dependent **FX** activation

SO Thrombosis Research (1997), 86(1), 57-67  
CODEN: THBRAA; ISSN: 0049-3848

AB The authors have found that synthetic peptides derived from the two  
epidermal growth factor-like domains of **factor VII** are  
inhibitors of tissue factor dependent factor X activation. Inhibition was  
most pronounced for a constrained sequence of amino acids corresponding to  
positions 91-102 of **factor VII**, Cys-Val-Asn-Glu-Asn-  
Gly-Gly-Cys-Glu-Gln-Tyr-Cys. The biol. activity appeared to be localized  
to the tripeptide "motif", Glu-Gln-Tyr, within the larger sequence. The  
cyclic peptide was also an inhibitor of tissue factor induced coagulation  
of plasma, using lipidated tissue factor or tissue factor expressed on the  
surface of living cells. However, it did not interfere with intrinsic  
coagulation. Inhibition of factor X activation was dose-dependent with an  
IC50 value of 350 .mu.M. Kinetic analyses revealed non-competitive  
inhibition with respect to factor X and suggested that the peptide  
sequence interferes with the **factor VII**/tissue  
factor/factor X complex formation and function. A pentapeptide analog of  
the putative pharmacophore was also a dose-dependent inhibitor of factor X  
activation with an IC50 value of 560 .mu.M, but the tripeptide,  
Glu-Gln-Tyr, alone was without effect. The authors' results suggest a  
direct role for the second epidermal growth factor-like domain of

**factor VII**, and in particular its loop I, in the formation and function of the **factor VII** / tissue factor / factor X complex.

L13 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2003 ACS

PY 1995  
1995  
1998  
1995  
1996  
1998  
1996  
1996  
1997  
1998  
1995  
1996  
1999

PATENT NO.                      KIND      DATE

	PATENT NO.	KIND	DATE	
PI	WO 9500541	A1	19950105	<--
	AU 9469755	A1	19950117	<--
	AU 691814	B2	19980528	
	ZA 9404337	A	19950227	<--
	EP 703923	A1	19960403	<--
	EP 703923	B1	19981007	
	CN 1125450	A	19960626	<--
	JP 08511794	T2	19961210	<--
	HU 74873	A2	19970228	<--
	AT 171950	E	19981015	<--
	NO 9505067	A	19951214	<--
	FI 9506055	A	19960126	<--
	US 5962418	A	19991005	<--

IN Stephens, Ross Wentworth; Orning, Lars; Sakariassen, Kjell Steinar

TI Preparation of **factor VII**-derived peptides

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

AB Peptides comprising the amino acid sequences of the formula (IA):  
CVNENGGCEQYCS, (IB): FCLPAFEGRNCE and/or (IC): RCHEGYSLLADGVST as well  
as peptide fragments thereof, esters, amides, salts and cyclic derivs.  
thereof, functional analogs thereof, and extended peptide chains carrying  
amino acids or peptides at the termini of the above sequences or fragments  
are prep. These peptides are for use in the prevention or inhibition of  
binding of tissue factor (TF) to the serine protease factor (FVIIa) or its  
inactive pro-enzyme **factor VII** (FVII) and in  
turn, limit the formation of the **FVII**/TF and the FVIIa/TF  
complex, which enhance the activation of **factor VII** to  
FVIIa and catalyze the conversion of factor X to its active form Xa in the  
blood clotting process, resp., and thereby are useful for reducing blood  
clot formation. WISYSDGD, YSDGDQC, and CVNENGGCEQYC, which were prep. by  
the solid phase method, at 0.5 mM in vitro inhibited 57, 55, and 78%,  
resp., the FVIIa/TF complex-mediated activation of factor X to factor Xa.

L13 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2003 ACS

PY 1995  
1995  
1995

PATENT NO.                      KIND      DATE

PI	WO 9500847	A1	19950105	<--
----	------------	----	----------	-----

AU 9469754            A1    19950117            <--  
 ZA 9404336            A    19950227            <--

IN    Stephens, Ross Wentworth; Oerling, Lars; Sakariassen, Kjell  
 TI    Immunoassay  
 SO    PCT Int. Appl., 19 pp.  
       CODEN: PIXXD2

AB    The present invention relates to an assay for the formation of  
       multi-protein complexes (e.g., **factor VII**-tissue  
       factor complex) in, e.g., body fluids by the steps of: (1) reacting a  
       first protein of a multi-protein complex with an immobilized first  
       antibody specific therefor which does not interfere with complex  
       formation; (2) optionally adding further proteins which form part of the  
       multi-protein complex; (3) optionally adding a test substance; (4) adding  
       the remaining protein(s) required for formation of the multi-protein  
       complex; (5) adding a labeled second antibody specific to a protein added  
       in step (4); and (6) detecting and optionally detg. the amt. of the second  
       antibody immobilized as an indication of multi-protein complex formation.  
       Such an assay can be used to det. whether or to what degree a naturally  
       produced multi-protein complex is formed by an individual. In this way  
       any malfunction in formation of a multi-protein complex, for example due  
       to a genetic disorder or physiol. disturbance can be ascertained.  
       Examples are given of the detn. of the multi-protein complex  
       **factor VII**-tissue factor by ELISA and use of this assay  
       to analyze human blood plasma.

L13   ANSWER 4 OF 13   CAPLUS   COPYRIGHT 2003 ACS  
 PY    1994  
       1994  
       1994  
       1995

	PATENT NO.	KIND	DATE	
	-----	----	-----	
PI	WO 9409034	A1	19940428	<--
	ZA 9307553	A	19940503	<--
	AU 9351458	A1	19940509	<--
	EP 668875	A1	19950830	<--

IN    Eisenberg, Paul; Rylatt, Dennis Brian; Hillyard, Carmel Judith; Bundesen,  
       Peter Gregory  
 TI    Directing anticoagulants to blood clots using conjugates with ligands for  
       clot proteins and their preparation and use  
 SO    PCT Int. Appl., 30 pp.  
       CODEN: PIXXD2

AB    Anticoagulants are directed to clots by conjugating them with ligands for  
       clot proteins such as an antibody to fibrin. The clot-targeting,  
       anticoagulant mol. may also include a thrombolytic coupled to the  
       clot-targeting binding mol. or a thrombolytic coupled to the  
       anticoagulant. Conjugates of the Fab-SH fragment of anti-thrombin  
       antibody DD-3B6/22 and the anticoagulant peptide PPACK were prepd. by std.  
       methods. The conjugate was able to bind thrombin and the D-dimer and to  
       inhibit thrombin action in a dose-dependent manner. The chem. synthesis  
       of conjugates of the antibody and hirudin analogs and the cloning of genes  
       for antibody fragments for prepn. of conjugates by expression of cloned  
       genes for fusion proteins are described.

L13   ANSWER 5 OF 13   USPATFULL  
 PI    US 6121435            20000919            <--  
 IN    Vlasuk, George Phillip, Carlsbad, CA, United States  
       Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium  
       Messens, Joris Hilda Lieven, Dilbeek, Belgium  
       Lauwereys, Marc Josef, Haaltert, Belgium

LaRoche, Yves Rene, Bruxelles, Belgium  
 Jespers, Laurent Stephane, Tervuren, Belgium  
 Gansemans, Yannick Georges Jozef, Ichtegem, Belgium  
 Moyle, Matthew, Boulder, CO, United States  
 Bergum, Peter W., San Diego, CA, United States

TI Nematode-extracted serine protease inhibitors and anticoagulant proteins  
 AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

## L13 ANSWER 6 OF 13 USPATFULL

PI US 6096877 20000801 <--

IN Vlasuk, George Phillip, Carlsbad, CA, United States  
 Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium  
 Messens, Joris Hilda Lieven, Dilbeek, Belgium  
 Lauwereys, Marc Josef, Haaltert, Belgium  
 LaRoche, Yves Rene, Brussels, Belgium  
 Jespers, Laurent Stephane, Tervuren, Belgium  
 Gansemans, Yannick Georges Jozef, Ichtegem, Belgium  
 Moyle, Matthew, Boulder, CO, United States  
 Bergum, Peter W., San Diego, CA, United States

TI Nematode-extracted serine protease inhibitors and anticoagulant proteins  
 AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

## L13 ANSWER 7 OF 13 USPATFULL

PI US 6090916 20000718 <--

WO 9612021 19960425 <--

IN Vlasuk, George Phillip, Carlsbad, CA, United States  
 Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium  
 Messens, Joris Hilda Lieven, Dilbeek, Belgium  
 Lauwereys, Marc Josef, Haaltert, Belgium  
 LaRoche, Yves Rene, Brussels, Belgium  
 Jespers, Laurent Stephane, Tervuren, Belgium  
 Gansemans, Yannick Georges Jozef, Ichtegem, Belgium  
 Moyle, Matthew, Boulder, CO, United States  
 Bergum, Peter W., San Diego, CA, United States

TI Nematode-extracted serine protease inhibitors and anticoagulant proteins  
 AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

## L13 ANSWER 8 OF 13 USPATFULL

PI US 6087487 20000711 <--

IN Vlasuk, George Phillip, Carlsbad, CA, United States  
 Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium  
 Messens, Joris Hilda Lieven, Dilbeek, Belgium  
 Lauwereys, Marc Josef, Haaltert, Belgium  
 LaRoche, Yves Rene, Brussels, Belgium  
 Jespers, Laurent Stephane, Tervuren, Belgium

Gansemans, Yannick Georges Jozef, Ichtegem, Belgium  
 Moyle, Matthew, Boulder, CA, United States  
 Bergum, Peter W., San Diego, CA, United States  
 TI Nematode-extracted serine protease inhibitors and anticoagulant proteins  
 AB Proteins which have activity as anticoagulants and/or serine protease  
 inhibitors and have at least one NAP domain and are described. Certain  
 of these proteins have factor Xa inhibitory activity and others have  
 activity as inhibitors of factor VIIa/TF. These proteins can be isolated  
 from natural sources as nematodes, chemically synthesized or made by  
 recombinant methods using various DNA expression systems.

## L13 ANSWER 9 OF 13 USPATFULL

PI US 6046318 20000404 <--  
 IN Vlasuk, George Phillip, Carlsbad, CA, United States  
 Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium  
 Messens, Joris Hilda Lieven, Dilbeek, Belgium  
 Lauwereys, Marc Josef, Haaltert, Belgium  
 LaRoche, Yves Rene, Bruxelles, Belgium  
 Jespers, Laurent Stephane, Tervuren, Belgium  
 Gansemans, Yannick Georges Jozef, Ichtegem, Belgium  
 Moyle, Matthew, Boulder, CO, United States  
 Bergum, Peter W., San Diego, CA, United States  
 TI Nematode-extracted serine protease inhibitors and anticoagulant proteins  
 AB Proteins which have activity as anticoagulants and/or serine protease  
 inhibitors and have at least one NAP domain and are described. Certain  
 of these proteins have factor Xa inhibitory activity and others have  
 activity as inhibitors of factor VIIa/TF. These proteins can be isolated  
 from natural sources as nematodes, chemically synthesized or made by  
 recombinant methods using various DNA expression systems.

## L13 ANSWER 10 OF 13 USPATFULL

PI US 6040441 20000321 <--  
 IN Vlasuk, George Phillip, Carlsbad, CA, United States  
 Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium  
 Messens, Joris Hilda Lieven, Dilbeek, Belgium  
 Lauwereys, Marc Josef, Haaltert, Belgium  
 LaRoche, Yves Rene, Brussels, Belgium  
 Jespers, Laurent Stephane, Tervuren, Belgium  
 Gansemans, Yannick Georges Jozef, Ichtegem, Belgium  
 Moyle, Matthew, Boulder, CO, United States  
 Bergum, Peter W., San Diego, CA, United States  
 TI Nematode-extracted serine protease inhibitors and anticoagulant proteins  
 AB Proteins which have activity as anticoagulants and/or serine protease  
 inhibitors and have at least one NAP domain and are described. Certain  
 of these proteins have factor Xa inhibitory activity and others have  
 activity as inhibitors of factor VIIa/TF. These proteins can be isolated  
 from natural sources as nematodes, chemically synthesized or made by  
 recombinant methods using various DNA expression systems.

## L13 ANSWER 11 OF 13 USPATFULL

PI US 5962418 19991005 <--  
 WO 9500541 19950105  
 IN Sakariassen, Kjell Steinar, Oslo, Norway  
 Stephens, Ross Wentworth, Copenhagen, Denmark  
 Orning, Lars, Oslo, Norway  
 TI **Factor VII**-derived peptides  
 AB The present invention relates to compounds comprising the amino acid  
 sequences of the formulae (IA): -CVNENGGEQYCSN-, (IB): -FCLPAFEGRNCE-  
 and/or (IC): -RCHEGYSLADGVST- as well as peptide fragments thereof,  
 esters, amides, salts and cyclic derivatives thereof, functional

09921880

analogues thereof and extended peptide chains carrying amino acids or peptides at the termini of the above sequences or fragments, for use in the prevention or inhibition of binding of tissue factor to **FVII**

L13 ANSWER 12 OF 13 USPATFULL

PI US 5955294 19990921 <--  
IN Vlasuk, George Phillip, Carlsbad, CA, United States  
Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium  
Messens, Joris Hilda Lieven, Antwerp, Belgium  
Lauwereys, Marc Josef, Haaltert, Belgium  
LaRoche, Yves Rene, Brussels, Belgium  
Jespers, Laurent Stephane, Tervuren, Belgium  
Ganseman, Yannick Georges Jozef, Ichtegem, Belgium  
Moyle, Matthew, Escondido, CA, United States  
Bergum, Peter W., San Diego, CA, United States  
TI Nematode-extracted serine protease inhibitors and anticoagulant proteins  
AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

L13 ANSWER 13 OF 13 USPATFULL

PI US 5891664 19990406 <--  
IN Dan.o slashed. , Keld, Charlottenlund, Denmark  
Blasi, Francesco, Charlottenlund, Denmark  
Roldan, Ann Louring, Vallensb.ae butted.k, Denmark  
Cubellis, Maria Vittoria, Napoli, Italy  
Masucci, Maria Teresa, Napoli, Italy  
Appella, Ettore, Chevy Chase, MD, United States  
Schleunig, Wolf-Dieter, Berlin, Germany, Federal Republic of  
Behrendt, Niels, Bagsv.ae butted.rd, Denmark  
R.o slashed.nne, Ebbe, Copenhagen, Denmark  
Kristensen, Peter, Copenhagen, Denmark  
Pollanen, Jari, Espoo, Finland  
Salonen, Eeva-Marjatta, Espoo, Finland  
Stephens, Ross W., Helsinki, Finland  
Tapiovaara, Hannele, Helsinki, Finland  
Vaheri, Antti, Kauniainen, Finland  
M.o slashed.ller, Lisbeth Birk, Bagsv.ae butted.rd, Denmark  
Ellis, Vincent, Copenhagen, Denmark  
Lund, Leif R.o slashed.ge, Copenhagen, Denmark  
Ploug, Michael, Copenhagen, Denmark  
Pyke, Charles, S.o slashed.borg, Denmark  
Patthy, Laszlo, Budapest, Hungary  
TI Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)  
AB Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.

=> d hist

08/03/01

09921880

(FILE 'HOME' ENTERED AT 11:06:25 ON 30 JAN 2003)

FILE 'REGISTRY' ENTERED AT 11:06:52 ON 30 JAN 2003

L1 168545 S C.....C/SQSP  
L2 60610 S L1 AND SQL<=210

FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, SCISEARCH, PCTFULL, USPATFULL,  
USPAT2, EUROPATFULL' ENTERED AT 11:29:46 ON 30 JAN 2003

FILE 'REGISTRY' ENTERED AT 11:32:16 ON 30 JAN 2003

L3 14 S CWTWETC/SQSP

FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, SCISEARCH, PCTFULL, USPATFULL,  
USPAT2, EUROPATFULL' ENTERED AT 11:33:06 ON 30 JAN 2003

L4 3 S L3

FILE 'REGISTRY' ENTERED AT 11:35:06 ON 30 JAN 2003

L5 4615 S L1 AND SQL<=20  
L6 1711 S L1 AND SQL<=10

FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, SCISEARCH, PCTFULL, USPATFULL,  
USPAT2, EUROPATFULL' ENTERED AT 11:36:13 ON 30 JAN 2003

L7 2997 S L5  
L8 752 S L7 AND (FACTOR OR THROMBOSIS)  
L9 18 S L7 AND (FACTOR (W) VII)  
L10 18 DUP REM L9 (0 DUPLICATES REMOVED)  
L11 530 S L7 AND ((FACTOR (W) VII) OR FVII OR FX OR X)  
L12 19 S L7 AND ((FACTOR (W) VII) OR FVII OR FX)  
L13 13 S L12 AND PY<=2000

08/03/01